Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Delaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo ...

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...

BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based ...

One study suggests these drugs could increase depression risk in heart attack survivors who retained normal heart pumping ...

However, emerging research suggests one subtle way that your sleep quality might become compromised without you realizing ...

Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, is the leading cause of acquired heart disease in developed countries, with the potential of ...

In MI patients with preserved heart function, beta-blockers are linked to higher depressive symptoms, indicating a need for ...